Stem cell

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

Retrieved on: 
Wednesday, March 6, 2024

Research Nester says , "The global pancreatic cancer market size is slated to expand at ~18% CAGR between 2024 and 2036.

Key Points: 
  • Research Nester says , "The global pancreatic cancer market size is slated to expand at ~18% CAGR between 2024 and 2036.
  • The American Cancer Society's estimates for pancreatic cancer in the United States for 2024 are: "About 66,440 people (34,530 men and 31,910 women) will be diagnosed with pancreatic cancer.
  • Pancreatic cancer accounts for about 3% of all cancers in the US and about 7% of all cancer deaths."
  • Biotech/oncology stocks targeting the growing global pancreatic cancer market have made headlines with recent developments and breakthroughs in treatments.

Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting

Retrieved on: 
Friday, March 8, 2024

WATERTOWN, Mass., March 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that its preclinical data demonstrating the therapeutic potential of its potent and selective heterobifunctional degraders of STAT6 (KT-621) and TYK2 (KT-294) are being presented in the poster session at the American Academy of Dermatology’s Annual Meeting in San Diego, California. Kymera’s oral STAT6 and TYK2 degraders have the potential to address multiple immune-mediated diseases and overcome the limitations of existing technologies and agents. Today’s poster presentations mark the first time that data from a STAT6 targeted agent and a TYK2 degrader have been shared at a major medical meeting. Based on the results generated to date, Kymera intends to initiate Phase 1 testing for KT-621 and KT-294 in the in the second half of 2024 and the first half of 2025, respectively. Data from both Phase 1 trials are expected to be reported in 2025.

Key Points: 
  • Kymera’s oral STAT6 and TYK2 degraders have the potential to address multiple immune-mediated diseases and overcome the limitations of existing technologies and agents.
  • Today’s poster presentations mark the first time that data from a STAT6 targeted agent and a TYK2 degrader have been shared at a major medical meeting.
  • “Our differentiated strategy to targeted protein degradation has resulted in an industry-leading immunology pipeline of oral degrader medicines, each with the potential to treat multiple complex immuno-inflammatory diseases.
  • At low daily oral doses, preclinical studies with KT-621 demonstrated near full in vivo STAT6 degradation in disease-relevant tissues that was well-tolerated.

Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells

Retrieved on: 
Thursday, March 7, 2024

These data, which highlight the platform’s robust anti-tumor activity against gastric cancer will be presented on April 9th, 2024.

Key Points: 
  • These data, which highlight the platform’s robust anti-tumor activity against gastric cancer will be presented on April 9th, 2024.
  • Celularity is developing a platform to combine a broad portfolio of cell therapies with various approved antibodies to address multiple cancers and other conditions.
  • Celularity’s preclinical asset, PT-CD16VS, is initially being developed in combination with trastuzumab, a cancer drug, for treating HER2-positive cancers.
  • “These data demonstrate the promise and potential of combining Celularity’s cell therapy assets with currently available therapies to address difficult-to-treat cancers,” said Dr. Robert Hariri, Celularity’s CEO and Founder.

Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference

Retrieved on: 
Thursday, March 7, 2024

The data presented was garnered from pre-clinical studies that Telomir previously disclosed it was undertaking.

Key Points: 
  • The data presented was garnered from pre-clinical studies that Telomir previously disclosed it was undertaking.
  • The data presented further demonstrated how Telomir-1 increases telomere length and its potential to successfully affect age-related inflammatory conditions.
  • The collaboration is expected to help accelerate the development of Telomir-1, improve its safety profile, and significantly reduce the research and development costs of Telomir’s drug development program.
  • To be added to the Telomir Pharmaceuticals email distribution list, please email [email protected] with TELO in the subject line.

Ludwig Enterprises Inc. (OTC:LUDG) Announces Patent Filing for Breakthrough in Identifying mRNA Genes Associated with Certain Cancers

Retrieved on: 
Wednesday, March 6, 2024

The Company’s mRNA for Life™ is a one-of-the-kind noninvasive at-home sceening test for genes that could be associated with cancer.

Key Points: 
  • The Company’s mRNA for Life™ is a one-of-the-kind noninvasive at-home sceening test for genes that could be associated with cancer.
  • This test allows a person to make themselves a priority and could be a signal to seek a medical examination.
  • The Company selected for measurement 48 distinct mRNA genes in stored specimens from patients afflicted with breast, bladder or colorectal cancer.
  • mRNA levels were analyzed using machine learning artificial intelligence (AI) to identify markers of genetic expression involved in separate cancers.

Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal

Retrieved on: 
Tuesday, March 5, 2024

BALTIMORE, March 05, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to affect age reversal, today announced that Michael F. Roizen, MD, a leader in age-related medicine and an existing advisor to the Company, will be increasing his role in the coming months as a Special Advisor on Age Reversal.

Key Points: 
  • A board-certified internist and anesthesiologist, Dr. Roizen has been instrumental in the development of many successful ventures.
  • He also served 16 years on Food and Drug Administration (FDA) advisory committee and chaired one for two years.
  • Chris Chapman, MD, co-founder, chairman, chief executive officer and president of Telomir, stated, “Telomir's groundbreaking work has captured the attention and imagination of the industry.
  • We look forward to his continued contributions to our efforts.”
    To be included in the Telomir Pharmaceuticals email distribution list, please email [email protected] with TELO in the subject line.

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, February 21, 2024

R&D Expenses: R&D expenses were $95.1 million for the fourth quarter of 2023, compared to $103.6 million for the fourth quarter of 2022.

Key Points: 
  • R&D Expenses: R&D expenses were $95.1 million for the fourth quarter of 2023, compared to $103.6 million for the fourth quarter of 2022.
  • G&A Expenses: General and administrative expenses were $16.5 million for the fourth quarter of 2023, compared to $21.2 million for the fourth quarter of 2022.
  • Collaboration Expense: Collaboration expense, net, was $20.0 million for the fourth quarter of 2023, compared to $6.8 million for the fourth quarter of 2022.
  • Net Income (Loss): Net income was $89.3 million for the fourth quarter of 2023, compared to a net loss of $110.6 million for the fourth quarter of 2022.

3D Cell Cultures Technologies Report 2024, Featuring Profiles of Leading Market Participants Including Abcam, Agilent Technologies, Corning, Merck, Beckman Coulter and Synvivo - ResearchAndMarkets.com

Retrieved on: 
Monday, February 26, 2024

3D cell culture technologies are a powerful tool for studying cell biology, disease mechanisms and drug discovery.

Key Points: 
  • 3D cell culture technologies are a powerful tool for studying cell biology, disease mechanisms and drug discovery.
  • 3D cell culture models mimic the 3D structure and cell-cell interactions that are found in real tissues, making them more accurate and predictive than traditional 2D cell culture models.
  • There are a variety of 3D cell culture technologies available, including:
    Scaffold-based 3D cell culture: This approach uses a scaffold to provide a 3D support structure for cells to grow on.
  • Bioprinting: This approach uses a 3D printer to deposit cells and biomaterials layer-by-layer to create complex 3D cell culture models.

Rejuvenate Bio Announces Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in the Journal Cellular Reprogramming

Retrieved on: 
Thursday, February 22, 2024

The study, titled " Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in Aged Mice ," reveals promising advancements in combating age-related diseases and extending lifespan through cellular rejuvenation.

Key Points: 
  • The study, titled " Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in Aged Mice ," reveals promising advancements in combating age-related diseases and extending lifespan through cellular rejuvenation.
  • While aging cannot be prevented, interventions targeting cellular processes offer potential for mitigating its impact on health and lifespan in the elderly.
  • Rejuvenate Bio's research focuses on partial reprogramming using the Yamanaka factors, specifically OCT4, SOX2, and KLF4 (OSK), to reverse age-related changes.
  • These results may have important implications for the development of partial reprogramming interventions to reverse age-associated diseases in the elderly population.”

Charles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells

Retrieved on: 
Tuesday, February 20, 2024

The collaboration provides Charles River with broad access to highly characterized and unique stem cell lines, including high-quality embryonic stem (ES) cells and induced pluripotent stem cells (iPSCs) as research tools to support development of new therapeutics.

Key Points: 
  • The collaboration provides Charles River with broad access to highly characterized and unique stem cell lines, including high-quality embryonic stem (ES) cells and induced pluripotent stem cells (iPSCs) as research tools to support development of new therapeutics.
  • Pluristyx offers a unique product and technology platform in the stem cell biology field for development of new therapies while reducing timelines and downstream costs.
  • Through the agreement, Charles River will distribute Pluristyx’s wild-type and genetically engineered iPSCs as well as their comprehensive portfolio of normal and disease state ES cell lines.
  • The addition of Pluristyx’s offerings complements Charles River’s expansive portfolio of high-quality human cellular materials.